^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

BCL2 (B-cell CLL/lymphoma 2)

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
1d
Trial completion
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
|
cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
1d
Integration of network toxicology and bioinformatics identifies key targets and pathways in 1,3-butadiene-induced nephrotoxicity. (PubMed, Int J Environ Health Res)
Additionally, using the TCGA database, we found that these targets have diagnostic and prognostic significance in renal cancer. Our findings suggest that BCL2, CASP3, MMP9, SIRT1, and TNF may play crucial roles in both nephrotoxicity and renal cancer progression, offering new insights into the molecular mechanisms of 1,3-BD-induced renal injury and potential intervention targets.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • SIRT1 (Sirtuin 1)
1d
Enrollment open • Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule)
|
cyclophosphamide • fludarabine IV
1d
Turning Off the Powerhouse: Mitochondria-Targeted DPPZ-Ru(II)/Ir(III)/Re(I) Complexes Trigger Dual Mitophagy and Apoptosis To Halt Triple-Negative Breast Cancer. (PubMed, J Med Chem)
Notably, it also triggers mitophagy through PINK1/Parkin upregulation, offering dual mitochondrial-targeted cytotoxicity. These findings position [UDRu] as a next-generation Ru(II) complex with multitargeted action, holding significant promise for overcoming resistance in TNBC therapy.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • PINK1 (PTEN Induced Kinase 1)
1d
Incidentally Found Olfactory Schwannoma: A Rare Case Report. (PubMed, Clin Med Insights Case Rep)
Comprehensive imaging and histopathological evaluation are crucial for accurate diagnosis. Early detection and total resection contribute to favorable neurological outcomes in asymptomatic patients.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CD34 (CD34 molecule) • GFAP (Glial Fibrillary Acidic Protein)
1d
Plasmacytoma of the Cervix Possibly Caused by Neglected Pessary: A Case Report and Literature Review. (PubMed, Iran J Pathol)
This case highlights the importance of considering cervical EMP in atypical cytology and suggests a possible link to chronic pessary-induced inflammation. Early diagnosis through histopathology and immunohistochemistry is essential.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • SDC1 (Syndecan 1)
1d
Role of immunohistochemistry in differentiating between reactive and malignant lymphoid hyperplasia - A cross-sectional study. (PubMed, Bioinformation)
The analysis revealed that IHC not only confirmed lineage specificity but also helped to identify aberrant antigen expression and proliferative indices characteristic of malignancy. Thus, we show the pivotal role of IHC in improving diagnostic accuracy, reducing misclassification and guiding appropriate therapeutic decisions in patients with lymphoid hyperplasia.
Observational data • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MME (Membrane Metalloendopeptidase)
2d
Exosomes derived from bone marrow mesenchymal stem cells facilitate repair of radiation-Induced skin injury by attenuating inflammation and apoptosis. (PubMed, Sci Rep)
Western blot analysis of apoptosis-related proteins showed that BMSCs-Exos increased the Bcl-2 expression and reduced Bax expression and promoted phosphorylation of the Akt signaling pathway, which implied suppression of cellular apoptosis. In summary, our findings demonstrate that BMSCs-Exos promote RISI repair by regulating the inflammatory microenvironment, and inhibiting cell apoptosis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • CD31 (Platelet and endothelial cell adhesion molecule 1) • IL1B (Interleukin 1, beta) • MRC1 (Mannose Receptor C-Type 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CD86 (CD86 Molecule)
2d
Synthesis or preparation, physicochemical characterization, and H460 cell inhibition of selenium nanoparticles stabilized by Marsdenia tenacissima residue polysaccharide. (PubMed, Int J Biol Macromol)
WB and RT-qPCR analysis further confirmed this dual mechanism, revealing downregulation of key cell cycle regulators (Cyclin A/D and CDK2/4) and activation of the mitochondrial apoptotic pathway, characterized by an increased Bax/Bcl-2 ratio and caspase-3 activation. This study not only presents a sustainable strategy for utilizing Marsdenia tenacissimaresidue but also highlights the promise of polysaccharide-based nanodrugs in cancer therapy.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCNA2 (Cyclin A2) • CDK2 (Cyclin-dependent kinase 2)
3d
Phthalate Metabolite, Mono(2-Ethyl-5-Hydroxyhexyl) Phthalate (MEHHP), Promotes Uterine-Fibroid-Associated Phenotypes in Myometrial Stem Cell-Derived 3D Organoids. (PubMed, Environ Toxicol)
These findings related to MYOF-specific effects, as compared to MYON, emphasize that these differences are statistically significant and relevant to UF risk. It can shed insight on how phthalates exposures may impact UF pathogenesis and provide a basis for exploring targeted therapeutic strategies.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BAX (BCL2-associated X protein) • CA9 (Carbonic anhydrase 9) • CASP3 (Caspase 3) • FN1 (Fibronectin 1) • TGFB1 (Transforming Growth Factor Beta 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • PCNA (Proliferating cell nuclear antigen)
3d
Enrollment open • Pan tumor
|
BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule)
3d
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
P2, N=28, Active, not recruiting, Patrick C. Johnson, MD | Recruiting --> Active, not recruiting
Enrollment closed
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV